Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Front Pharmacol. 2020 Feb 20;10:1686. doi: 10.3389/fphar.2019.01686. eCollection 2019.

2.

Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Ther Drug Monit. 2019 Aug;41(4):528-532. doi: 10.1097/FTD.0000000000000656.

PMID:
31259882
3.

High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.

Somogyi AA, Barratt DT, Phillips EJ, Moore K, Ilyas F, Gabb GM.

Br J Clin Pharmacol. 2019 Sep;85(9):2163-2169. doi: 10.1111/bcp.14025. Epub 2019 Jul 19.

PMID:
31206740
4.

The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population.

Chiang DLC, Rice DA, Helsby NA, Somogyi AA, Kluger MT.

Pain Med. 2019 Sep 1;20(9):1803-1814. doi: 10.1093/pm/pnz049.

PMID:
30889241
5.

A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial.

Gálvez Ortiz V, Glue P, Somogyi AA, Martin D, Alonzo A, Rodgers A, Mitchell PB, Li A, Huggins C, Loo CK.

J Psychopharmacol. 2019 Feb;33(2):260-261. doi: 10.1177/0269881118822147. No abstract available.

PMID:
30773113
6.

Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation.

Sallustio BC, Noll BD, Coller JK, Tuke J, Russ G, Somogyi AA.

Br J Clin Pharmacol. 2019 May;85(5):1015-1020. doi: 10.1111/bcp.13880. Epub 2019 Mar 6.

PMID:
30690767
7.

Conference report: pharmacogenomics in special populations at WCP2018.

Suarez-Kurtz G, Aklillu E, Saito Y, Somogyi AA.

Br J Clin Pharmacol. 2019 Mar;85(3):467-475. doi: 10.1111/bcp.13828. Epub 2019 Jan 24.

8.

Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Pharmacogenet Genomics. 2019 Jan;29(1):9-17. doi: 10.1097/FPC.0000000000000360.

PMID:
30489455
9.

Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors.

Rice DA, Kluger MT, McNair PJ, Lewis GN, Somogyi AA, Borotkanics R, Barratt DT, Walker M.

Br J Anaesth. 2018 Oct;121(4):804-812. doi: 10.1016/j.bja.2018.05.070. Epub 2018 Jul 18.

10.

The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial.

Rowsell L, Wong KKH, Yee BJ, Eckert DJ, Somogyi AA, Duffin J, Grunstein RR, Wang D.

Thorax. 2019 Feb;74(2):177-184. doi: 10.1136/thoraxjnl-2018-211675. Epub 2018 Aug 30.

PMID:
30166422
11.

Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.

Md Dom ZI, Coller JK, Carroll RP, Tuke J, McWhinney BC, Somogyi AA, Sallustio BC.

Br J Clin Pharmacol. 2018 Oct;84(10):2433-2442. doi: 10.1111/bcp.13704. Epub 2018 Aug 7.

12.

Effects of Electroacupuncture on Opioid Consumption in Patients with Chronic Musculoskeletal Pain: A Multicenter Randomized Controlled Trial.

Zheng Z, Gibson S, Helme RD, Wang Y, Lu DS, Arnold C, Hogg M, Somogyi AA, Da Costa C, Xue CCL.

Pain Med. 2019 Feb 1;20(2):397-410. doi: 10.1093/pm/pny113.

PMID:
29893942
13.

Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats.

Licari G, Milne RW, Somogyi AA, Sallustio BC.

Pharmacol Res Perspect. 2018 Jun;6(3):e00406. doi: 10.1002/prp2.406. Epub 2018 May 22.

14.

Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.

Tucci JD, Pumuye PP, Helsby NA, Barratt DT, Pokeya PP, Hombhanje F, Somogyi AA.

Pharmacogenet Genomics. 2018 Jun;28(6):153-164. doi: 10.1097/FPC.0000000000000335. Review.

PMID:
29768302
15.

CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.

Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.

Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):320-326. doi: 10.1111/bcpt.13016. Epub 2018 May 7.

16.

Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.

Gálvez V, Li A, Huggins C, Glue P, Martin D, Somogyi AA, Alonzo A, Rodgers A, Mitchell PB, Loo CK.

J Psychopharmacol. 2018 Apr;32(4):397-407. doi: 10.1177/0269881118760660. Epub 2018 Mar 15.

PMID:
29542371
17.

Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.

Athanasos P, Ling W, Bochner F, White JM, Somogyi AA.

Pain Med. 2019 Jan 1;20(1):119-128. doi: 10.1093/pm/pny025.

18.

Genomic testing as a tool to optimise drug therapy.

Somogyi AA, Phillips E.

Aust Prescr. 2017 Jun;40(3):101-104. doi: 10.18773/austprescr.2017.027. Epub 2017 Jun 1. Review. No abstract available.

19.

A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol.

Currow D, Watts GJ, Johnson M, McDonald CF, Miners JO, Somogyi AA, Denehy L, McCaffrey N, Eckert DJ, McCloud P, Louw S, Lam L, Greene A, Fazekas B, Clark KC, Fong K, Agar MR, Joshi R, Kilbreath S, Ferreira D, Ekström M; Australian national Palliative Care Clinical Studies Collaborative (PaCCSC).

BMJ Open. 2017 Jul 17;7(7):e018100. doi: 10.1136/bmjopen-2017-018100.

20.

Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients.

Newcombe DAL, Somogyi AA, Bochner F, White JM.

Exp Clin Psychopharmacol. 2017 Jun;25(3):223-233. doi: 10.1037/pha0000114. Epub 2017 Apr 17.

PMID:
28414496
21.

CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.

Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA.

Clin Pharmacokinet. 2017 Aug;56(8):977-985. doi: 10.1007/s40262-016-0494-0.

PMID:
27995529
22.

Advances in drug metabolism and pharmacogenetics research in Australia.

Mackenzie PI, Somogyi AA, Miners JO.

Pharmacol Res. 2017 Feb;116:7-19. doi: 10.1016/j.phrs.2016.12.008. Epub 2016 Dec 9. Review.

PMID:
27956261
23.

Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial.

Gálvez V, Nikolin S, Ho KA, Alonzo A, Somogyi AA, Loo CK.

Compr Psychiatry. 2017 Feb;73:31-34. doi: 10.1016/j.comppsych.2016.10.012. Epub 2016 Nov 4.

PMID:
27886522
24.

Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.

Somogyi AA, Sia AT, Tan EC, Coller JK, Hutchinson MR, Barratt DT.

Pain. 2016 Nov;157(11):2458-2466.

PMID:
27649267
25.

Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant.

Glue P, Loo C, Rodgers A, Gálvez V, Somogyi AA, Mitchell PB.

World J Biol Psychiatry. 2017 Sep;18(6):489. doi: 10.1080/15622975.2016.1181782. Epub 2016 May 27. No abstract available.

PMID:
27232768
26.

Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.

Loo CK, Gálvez V, O'Keefe E, Mitchell PB, Hadzi-Pavlovic D, Leyden J, Harper S, Somogyi AA, Lai R, Weickert CS, Glue P.

Acta Psychiatr Scand. 2016 Jul;134(1):48-56. doi: 10.1111/acps.12572. Epub 2016 Mar 30.

PMID:
27028832
27.

Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis.

Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, Glue P, Lapidus K, McGirr A, Somogyi AA, Mitchell PB, Rodgers A.

Int J Neuropsychopharmacol. 2016 Apr 20;19(4). pii: pyv124. doi: 10.1093/ijnp/pyv124. Print 2016 Apr. Review.

28.

Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.

Lewis BC, Nair PC, Heran SS, Somogyi AA, Bowden JJ, Doogue MP, Miners JO.

Pharmacogenet Genomics. 2016 Jan;26(1):44-50. doi: 10.1097/FPC.0000000000000184.

PMID:
26513304
29.

Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes.

Martin JH, Phillips E, Thomas D, Somogyi AA.

Br J Clin Pharmacol. 2015 Nov;80(5):929-31. doi: 10.1111/bcp.12690. No abstract available.

30.

Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl.

Barratt DT, Klepstad P, Dale O, Kaasa S, Somogyi AA.

PLoS One. 2015 Sep 2;10(9):e0137179. doi: 10.1371/journal.pone.0137179. eCollection 2015.

31.

Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.

Khan MS, Barratt DT, Somogyi AA.

Xenobiotica. 2016;46(3):278-87. doi: 10.3109/00498254.2015.1060649. Epub 2015 Jul 10.

PMID:
26161459
32.

Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?

Currow DC, Quinn S, Ekstrom M, Kaasa S, Johnson MJ, Somogyi AA, Klepstad P.

BMJ Open. 2015 May 6;5(5):e006818. doi: 10.1136/bmjopen-2014-006818.

33.

CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA.

Br J Clin Pharmacol. 2015 Aug;80(2):276-84. doi: 10.1111/bcp.12614. Epub 2015 Jun 1.

34.

Editors' pick 2014.

Loke YK, Somogyi AA, Ferro A, Ritter JM.

Br J Clin Pharmacol. 2015 Mar;79(3):354-6. doi: 10.1111/bcp.12587. No abstract available.

35.

Pharmacogenetics of opioid response.

Somogyi AA, Coller JK, Barratt DT.

Clin Pharmacol Ther. 2015 Feb;97(2):125-7. doi: 10.1002/cpt.23. Epub 2014 Dec 9.

PMID:
25670515
36.

Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling.

Corrigan F, Wu Y, Tuke J, Coller JK, Rice KC, Diener KR, Hayball JD, Watkins LR, Somogyi AA, Hutchinson MR.

Brain Behav Immun. 2015 Mar;45:245-52. doi: 10.1016/j.bbi.2014.12.019. Epub 2014 Dec 24.

37.

BJCP 40th anniversary: moving forward, looking back.

Gilchrist A, Loke YK, Somogyi AA, Cohen AF, Ritter JM.

Br J Clin Pharmacol. 2014 Dec;78(6):1175-84. doi: 10.1111/bcp.12520. No abstract available.

38.

Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats.

Licari G, Somogyi AA, Milne RW, Sallustio BC.

Xenobiotica. 2015 Jan;45(1):3-9. doi: 10.3109/00498254.2014.942721. Epub 2014 Jul 22.

PMID:
25050791
39.

Pharmacogenomics of methadone maintenance treatment.

Somogyi AA, Barratt DT, Ali RL, Coller JK.

Pharmacogenomics. 2014 May;15(7):1007-27. doi: 10.2217/pgs.14.56. Review.

PMID:
24956254
40.

Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort.

Dooney NM, Sundararajan K, Ramkumar T, Somogyi AA, Upton RN, Ong J, O'Connor SN, Chapman MJ, Ludbrook GL.

BMC Anesthesiol. 2014 May 12;14:33. doi: 10.1186/1471-2253-14-33. eCollection 2014.

41.

Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.

Lai R, Katalinic N, Glue P, Somogyi AA, Mitchell PB, Leyden J, Harper S, Loo CK.

World J Biol Psychiatry. 2014 Sep;15(7):579-84. doi: 10.3109/15622975.2014.922697. Epub 2014 Jun 9.

PMID:
24910102
42.

Editors' report, November 2013.

Somogyi AA, Lewis LD, Cohen AF, Flockhart DA, Ferro A, Loke YK, Ritter JM.

Br J Clin Pharmacol. 2014 Mar;77(3):401-2. doi: 10.1111/bcp.12317. No abstract available.

43.

Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report.

Gálvez V, O'Keefe E, Cotiga L, Leyden J, Harper S, Glue P, Mitchell PB, Somogyi AA, DeLory A, Loo CK.

Biol Psychiatry. 2014 Aug 1;76(3):e1-2. doi: 10.1016/j.biopsych.2013.12.010. Epub 2014 Jan 3. No abstract available.

PMID:
24507509
44.

Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.

Barratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL, Tuke J, Somogyi AA.

Pharmacogenet Genomics. 2014 Apr;24(4):185-94. doi: 10.1097/FPC.0000000000000032.

PMID:
24469018
45.

Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia.

Mulholland CV, Somogyi AA, Barratt DT, Coller JK, Hutchinson MR, Jacobson GM, Cursons RT, Sleigh JW.

J Mol Neurosci. 2014 Apr;52(4):497-506. doi: 10.1007/s12031-013-0201-7. Epub 2013 Dec 19.

PMID:
24352713
46.

Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies.

Md Dom ZI, Noll BD, Coller JK, Somogyi AA, Russ GR, Hesselink DA, van Gelder T, Sallustio BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 15;945-946:171-7. doi: 10.1016/j.jchromb.2013.11.056. Epub 2013 Dec 4.

PMID:
24342510
47.

Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies.

Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, Van Gelder T, Sallustio BC.

Ther Drug Monit. 2013 Oct;35(5):617-23. doi: 10.1097/FTD.0b013e31828e8162.

PMID:
23921430
48.

The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro.

Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA.

Drug Metab Dispos. 2013 Jun;41(6):1264-72. doi: 10.1124/dmd.113.051631. Epub 2013 Apr 2.

PMID:
23550066
49.

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics.

Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJ, Somogyi AA.

Pharmgenomics Pers Med. 2012;5:53-62. doi: 10.2147/PGPM.S29272. Epub 2012 Apr 18.

50.

The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea.

Wang D, Somogyi AA, Yee BJ, Wong KK, Kaur J, Wrigley PJ, Grunstein RR.

Respir Physiol Neurobiol. 2013 Feb 1;185(3):526-32. doi: 10.1016/j.resp.2012.11.014. Epub 2012 Dec 1.

PMID:
23207373

Supplemental Content

Loading ...
Support Center